Despite improvements in diagnostic and therapeutic approaches, lung cancer is the major cause of cancer-related deaths ( 1 , 2 ) . Non -small-cell lung cancer (NSCLC), the major form of lung cancer, is classifi ed into three histologic types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma is the most frequent histologic type of NSCLC in both sexes in many parts of the world. Although tobacco smoking is the cause of most lung cancers, it is less strongly associated with adenocarcinoma than with other histologic types ( 3 ) . Lung cancer is also characterized by the accumulation of multiple genetic and/or epigenetic alterations, including those that result in the activation of oncogenes and the inactivation of tumor suppressor genes ( 4 -6 ) . A better understanding of the molecular mechanism by which these alterations affect lung cancer pathogenesis would provide new and more effective strategies for chemoprevention, early diagnosis, and targeted treatment ( 7 ) .
Deregulation of protein kinase activity is common in malignancies ( 8 , 9 ) and has led to the development of therapies that target these oncogenes ( 10 ) . One such therapy, which has been widely used for the treatment of NSCLC, is gefi tinib (Iressa, ZD1839), a small-molecule tyrosine kinase (TK) inhibitor that inhibits the protein kinase activity of epidermal growth factor receptor (EGFR), which is highly expressed in many epithelial cancers, including lung cancers ( 11 ) . Although results of several preclinical studies and clinical trials have reported mixed results ( 12 -15 ) , the mechanisms of the antitumor effect and drug sensitivity of TK inhibitors have not been fully established because neither the expression nor the phosphorylation status of EGFR was associated with patient response ( 16 ) . Nonetheless, some patients have dramatic and durable responses to such therapy.
Reports of lung cancers bearing mutations in the EGFR gene have generated considerable interest because such mutations are associated with an increased sensitivity to gefi tinib therapy ( 17 -19 ) . All of the mutations detected are located within the TK domain of the EGFR gene, where gefi tinib competes with adenosine triphosphate (ATP) for binding to the protein; cells containing these mutations are responsive to the principal ligand (i.e., EGF) and show increased sensitivity to gefi tinib in vitro ( 17 ) . The TK domain EGFR mutations are more frequently found in NSCLCs with adenocarcinoma histology than in those with other histologies, in females than in males, in patients from Japan than in patients from the United States, and in never smokers than in current or former smokers ( 17 -19 ) , the same subpopulations that have the highest response rates to gefi tinib ( 14 , 15 , 20 , 21 ) .
To examine the role of EGFR TK domain mutations in lung cancer pathogenesis, we searched for EGFR TK domain mutations in genomic DNA isolated from primary lung tumors from Japan, Taiwan, the United States, and Australia. Our goal was to examine the associations between EGFR TK domain mutation status and patient sex, age at diagnosis, tumor histology, clinical stage, smoking history, and ethnicity. We also examined EGFR TK domain mutations in genomic DNA from nonmalignant lung tissue from many of the patients and from other epithelial cancer samples. EGFR signaling infl uences multiple downstream pathways, including Ras/Raf/mitogen-activated protein kinase, JAK-STAT cytokine, and phosphatidylinositol 3 ′ -kinase (PI3K)/ Akt pathways, which affect cell proliferation, survival, and apoptosis. Several genes in the RAS, RAF, and phosphatidylinositol 3 ′ -kinase families have been found to be mutated in lung cancer, with KRAS gene mutations (especially in codons 12 and 13) especially frequent ( 8 , 9 , 22 ) . DNA sequences of human papillomavirus (HPV) strains 16 and 18 have been reported to be associated with lung cancers from Taiwan and are associated with the female sex and never smoking status ( 23 ) . Thus, we also examined the relationship between EGFR gene mutation status and KRAS gene mutation status or the presence of HPV DNA sequences.
P ATIENTS AND M ETHODS

Tumor Samples
We obtained 617 NSCLC tumors from patients undergoing surgical resection at Chiba University and Okayama University (Chiba and Okayama, Japan, respectively; n = 263), Veterans General Hospital (Taichung, Taiwan; n = 93), MD Anderson Cancer Center (Houston, TX; n = 160), and Prince Charles Hospital (Brisbane, Australia; n = 101). Tumors were collected at the time of surgical resection and kept frozen at − 80°C. All patients from Japan and Taiwan were of East Asian ethnicity. Among patients from the United States, 139 were white, eight were Hispanic, seven were black, and four were East Asian; ethnicity was not known for two patients. One of the Australian patients was East Asian; the rest were white. For the 524 patients from Japan, the United States, and Australia, we also obtained a sample of the corresponding nonmalignant lung tissue from a site located far from the tumor. Most of the tumors were unselected (i.e., collected sequentially; n = 519); the remaining tumors were selected from among patients with well-documented smoking histories from the United States (n = 80) and Australia (n = 18). Six primary small-cell lung cancers (SCLCs) were obtained from patients undergoing treatment at Chiba University, and 25 bronchial carcinoids and 5 large-cell neuroendocrine carcinomas (LCNECs) were obtained from patients undergoing treatment at MD Anderson Cancer Center. A total of 243 epithelial carcinomas arising at sites other than the lung were obtained from patients undergoing treatment at the hospitals affi liated with University of Texas Southwestern Medical Center, Dallas, TX (prostate, bladder, breast, and colorectal cancer) or from Catholic University, Santiago, Chile (gallbladder cancer).
Institutional Review Board permission and patient written informed consent were obtained at each collection site. Clinical information, including patient sex, age at diagnosis, tumor histology, clinical stage, and smoking history, were available for all patients, and valid survival data were available for 436 patients (182 from Japan, 159 from the United States, and 95 from Australia). Clinical staging of lung cancers was performed using the revised International System for Staging Lung Cancer ( 24 ) . All available pathology slides of adenocarcinomas from the U.S. NSCLCs (n = 97) were reviewed and reevaluated for bronchioloalveolar carcinoma (BAC) subtypes according to the World Health Organization (WHO) classifi cation of lung cancers (which defi nes BAC as a true noninvasive cancer without stromal, vascular, or pleural invasion) ( 25 ) . The slides were also scored for the presence of lepidic growth (a feature of BAC) in increments of 10% (with 100% representing pure, or true, BAC tumors). The Taiwanese patients had been previously examined for the presence of HPV types 16 and 18 DNA ( 23 ) .
DNA Extraction and Sequencing
Genomic DNA was isolated from primary tumor samples by overnight digestion with sodium dodecyl sulfate and proteinase K (Life Technologies Inc., Rockville, MD) at 37°C, followed by standard phenol-chloroform (1 volume:1 volume) extraction and ethanol precipitation.
Intron-based polymerase chain reaction (PCR) primers were used to amplify the seven exons comprising the entire TK domain of the EGFR gene. The primers were as follows (forward and reverse, respectively): exon 18 (5 ′ -AGCATGGTGAGGGCTGAG GTGAC-3 ′ and 5 ′ -ATATACAGCTTGCAAGGACTCTGG-3 ′ ), exon 19 (5 ′ -CCAGATCACTGGGCAGCATGTGGCACC-3 ′ and 5 ′ -AGCAGGGTCTAGAGCAGAGCAGCTGCC-3 ′ ), exon 20 (5 ′ -GATCGCATTCATGCGTCTTCACC-3 ′ and 5 ′ -TTGC TATCCCAGGAGCGCAGACC-3 ′ ), exon 21 (5 ′ -TCAGAG CCT GGCATGAACATGACCCTG-3 ′ and 5 ′ -GGTCCCTGGTGT CAGGAAAATGCTGG-3 ′ ), exon 22 (5 ′ -AATTAGGTCCAGA GTGAGTTAAC-3 ′ and 5 ′ -ACTTGCATGTCAGAGGATATAA TG-3 ′ ), exon 23 (5 ′ -CATCAAGAAACAGTAACCAGTAATG-3 ′ and 5 ′ -AAGGCCTCAGCTGTTTGGCTAAG-3 ′ ), and exon 24 (5 ′ -TTGACTGGAAGTGTCGCATCACC-3 ′ and 5 ′ -CATGTGA CAGAACACAGTGACATG-3 ′ ). All PCR assays were carried out in a 25-μ L volume that contained 100 ng of genomic DNA and 1.25 units of HotStarTaq DNA polymerase (QIAGEN Inc., Valencia, CA). DNA was amplifi ed for 33 cycles at 95°C for 30 seconds, 65°C for 30 seconds, and 72°C for 45 seconds, followed by a 7-minute extension at 72°C. The sequences of the intronbased PCR primers for used to amplify exon 2 of the KRAS gene were as follows (forward and reverse, respectively): 5 ′ -GTAT TAACCTTATGTGTGACA-3 ′ and 5 ′ -GTCCTGCACCAGTA ATATGC-3 ′ . DNA was amplifi ed for 33 cycles at 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, followed by a 7-minute extension at 72°C. All PCR products were incubated with exonuclease I and shrimp alkaline phosphatase (Amersham Biosciences Corp., Piscataway, NJ) according to the manufacturer's instructions and then sequenced directly using the Applied Biosystems PRISM dye terminator cycle sequencing method (Perkin-Elmer Corp., Foster City, CA). All sequence variants were confi rmed by sequencing the products of independent PCR amplifi cations in both directions.
Statistical Analyses
We used chi-square tests and Fisher's exact tests (when there were fewer than fi ve expected counts in the contingency table) to assess the relationship between EGFR gene mutations and each of the potentially infl uential factors, including ethnicity, sex, smoking status, and histologic subtype. We used logistic regression models, with EGFR gene mutation status as the outcome, to examine the effects of ethnicity, sex, smoking status, and histologic subtype, with adjustment for each factor. Kaplan-Meier curves were drawn for the two groups of patients (i.e., those with and without the mutations), and the difference in overall survival between the two groups was investigated by using a Cox proportional hazards model with adjustment for other survival-related risk factors, age, ethnicity, and histological subtype, given the mutation groups were time independent. The agreement between EGFR and KRAS gene mutation status was tested, and the kappa coeffi cient was determined. The agreement between mutation status for each of the four studied exons of the TK domain and ethnicity, sex, smoking status, and histologic type was tested among unselected patients with EGFR mutations. All statistical tests were two sided, and P values less than .05 were considered statistically signifi cant.
R ESULTS
Preliminary sequence analysis of the entire TK domain (exons 18 -24) of the EGFR gene of 96 unselected NSCLC samples indicated that all mutations were located within exons 18 -21, which encode the N lobe and part of the C lobe of EGFR ( Fig. 1 ). Our subsequent analyses were limited to these four exons. We detected mutations only in DNA extracted from NSCLC samples; no mutations were detected in DNA extracted from neuroendocrine lung tumors (SCLCs, LCNECs, and bronchial carcinoids) or prostate, bladder, breast, colorectal, or gallbladder carcinomas. EGFR TK domain mutations were detected in 130 (21%) of the 617 NSCLCs and in 120 (23%) of the 519 unselected NSCLCs ( Table 1 ) . Of the 120 unselected tumors with EGFR TK domain mutations, two had multiple mutations (see below). The frequency of mutations was greater for patients of East Asian ethnicity versus those of other ethnicities (30% versus 8%, P < .001), females versus males (42% versus 14%, P < .001), never smokers versus ever smokers (51% versus 10%, P < .001), and for adenocarcinomas versus other histologies (40% versus 3%, P < .001).
Among the adenocarcinoma patients from the United States or Australia, four (80%) of fi ve patients of East Asian ethnicity had an EGFR TK domain mutation, whereas only 12 (16%) of 75 patients of other ethnicities (mainly white) had an EGFR TK domain mutation ( P = .005). Of the four EGFR TK domain mutation-positive adenocarcinomas in patients of East Asian ethnicity, three were from males and two were from never smokers. Logistic regression models confi rmed that age and EGFR TK domain mutation status were independent. Because the distribution of age at diagnosis was not statistically signifi cant different between patients with and without EGFR TK domain mutations, we did not adjust for age in the logistic regression analyses. We examined associations between the variables after adjustment for each other, with EGFR TK domain mutation status as the outcome and all the factors as explanatory variables, and found no interactions.
Even when we confi ned our analysis to the subgroup with the highest frequencies of mutations, never smokers with adenocarcinomas (both selected and unselected cases combined, n = 157), the EGFR TK domain mutation frequency was statistically signifi cantly higher for patients from Japan and Taiwan than for those from the United States and Australia (64% versus 36%), both before and after adjustment for sex ( P = .003 and .004, respectively). For the 160 patients from the United States for whom we had detailed smoking data, 3% of current smokers, 8% of former smokers, and 20% of never smokers had EGFR TK domain mutations. Results of a test for trend revealed that smoking status was statistically signifi cantly associated with the presence of EGFR gene mutations (adjusted P trend = .02). There were no statistically signifi cant differences in mutational patterns with respect to sex, smoking status, or ethnicity.
Overall, we identifi ed a total 134 EGFR TK domain mutations among 130 tumors. In 95 of the 130 patients for whom adjacent (80) 11 (14) Male (43) 3 (7) .116 Never smoker (26) 7 (27) .043 Adenocarcinoma (44) 11 (25) <.001 Female (37) 8 (22) Smoker (54) 4 (7) Other (36) 0 (0) Australia (83) 6 (7) Male (58) 1 (2) .013 Never smoker (7) 4 (57) <.001 Adenocarcinoma (36) 5 (14) .081 Female (25) 5 (20) Smoker (76) nonmalignant lung tissue was available, mutations were absent from the nonmalignant tissue, indicating that the mutations were somatic in origin. The mutations consisted of three different types -in-frame deletions, single-nucleotide substitutions, and in-frame duplications/insertions -and all mutations were located within or near functionally important sites in the receptor ( Table 2 ; Fig. 1 ). In-frame deletions in exon 19 (11 types, labeled Δ 1 -Δ 11), involving three to seven codons centered around the uniformly deleted codons 747 to 749 (Leu-Arg-Glu sequence), accounted for 62 (46%) of the mutations detected. The in-frame deletions were occasionally accompanied by missense mutations at the carboxyl-terminal amino acid position fl anking the deletion. Missense mutations (n = 60, 45% of total mutations) in exons 18, 20, or 21 (nine types, labeled M1 -M9) were the second-most-common mutation, especially mutation L858R (M1) in exon 21 (n = 52, 39% of total mutations). In-frame duplications and/or insertions of one to three codons in exon 20 (eight types, labeled D1 -D8), involving amino acids 770 to 776, accounted for 12 (9%) of the mutations. We also detected one silent mutation in exon 18 at codon 718. Three tumors had multiple mutations (one tumor had two mutations, and two tumors had three mutations each); each of the remaining tumors had a single mutation. It has been reported that EGFR TK domain mutations are common among adenocarcinomas of the BAC subtype ( 17 , 19 ) . Therefore, two pathologists (I.I.W. and A.F.G.) who are familiar with the WHO classifi cation of lung cancers ( 25 ) reviewed the pathology slides for 97 adenocarcinomas from the United States. Seven of these adenocarcinomas (7%) were pure BAC tumors, and none of them had EGFR TK domain mutations. Seventeen adenocarcinomas (18%) were classifi ed as having any BAC features (including those classifi ed as pure BAC tumors). BAC features were present in four (27%) of 15 adenocarcinomas with EGFR TK domain mutations and in 13 (16%) of 82 adenocarcinomas without EGFR TK domain mutations ( Table 3 ). There were no statistically signifi cant differences between EGFR TK domain mutation frequencies and the presence or percentage of BAC features ( P = .29).
We examined the sequence electropherograms for clues about the relative ratios of the mutant and wild-type alleles in individual tumors. We focused on the electropherograms of tumors that had in-frame deletions or duplications/insertions because their interpretation was facilitated by the fact that the entire sequence downstream of those mutations differed from that of the wildtype allele. Tumor specimens invariably contain a considerable percentage of nonmalignant cells; we therefore interpreted electropherograms in which the peaks corresponding to the mutant sequence were equal to or greater than those of the corresponding wild-type sequence as indicating gene amplifi cation of the mutant allele. Using these criteria, we found that approximately 40% of the electropherograms suggested gene amplifi cation of the mutant allele ( Fig. 2 ) .
Because KRAS gene mutations in lung cancers are, like EGFR TK domain gene mutations, limited almost exclusively to adenocarcinomas ( 22 ), we also analyzed the adenocarcinomas for mutations in codons 12 and 13 of the KRAS gene (the codons mutated in the majority of lung cancers). We found that KRAS gene mutations were present in 50 (8%) of the 617 NSCLCs and were more frequently found in adenocarcinomas than in other histologic types (12% versus 2%; P < .001), in ever smokers than in never smokers (10% versus 4%; P =.01), and in patients from the United States and Australia than in patients from Japan and Taiwan (12% versus 5%; P = .001). There was no statistically signifi cant association between the frequency of KRAS gene mutations and sex (7% in males versus 10% in females; P = .4). None of the tumors we examined had mutations in both the EGFR TK domain and the KRAS gene.
Among the unselected (i.e., sequentially collected) adenocarcinoma patients, the EGFR TK domain mutation rates were similar for early-stage disease (i.e., stages I and II; 80 [38%] of 208 cases were mutation positive) and advanced disease (i.e., stages III and IV; 34 [44%] of 78 were mutation positive) ( P = .5). After we adjusted for other factors, including age at diagnosis, there was no statistically signifi cant difference in overall survival between patients whose tumors did and did not have EGFR TK domain mutations ( P = .5, Wald's chi-square test, Cox proportional hazards model; Fig. 3 ). We also analyzed survival data for patients whose tumors had either of the two most common EGFR TK domain mutations (the L858R missense mutation in exon 21 and an inframe deletion in exon 19). Compared with patients with no EGFR TK domain mutations, those with deletions in exon 19 had worse survival and those with the L858R mutation had better survival, but in neither case was the difference statistically signifi cant.
Of the 93 Taiwanese patients, 58 had been previously tested for the presence of high-risk strains 16 and 18 of HPV ( 23 ) .
Among the tested patients, 32 had tumors (55%) that tested positive for HPV DNA, and as previously reported ( 23 ), 75% of the HPV DNA-positive tumors were from females and 67% were from never smokers. We found that 12 of the 58 patients with known HPV DNA status had an EGFR TK domain mutation. The concordance between the two groups (i.e., both molecular changes present versus neither present) was 53% (chi-square test; P = .42).
D ISCUSSION
A detailed study of mutation patterns within the EGFR gene and their associations with clinicopathologic features of lung cancers is essential because preliminary data have suggested that lung cancer patients whose tumors have EGFR TK domain mutations respond better than those without such mutations to drugs that target the TK domain of the gene ( 17 -19 ) . We tested a large number of primary lung and other cancers for EGFR TK domain mutations and explored the relationship between EGFR TK domain mutation status and multiple parameters associated with lung carcinogenesis, including KRAS gene mutation status and the presence of HPV DNA. We detected EGFR TK domain mutations only in lung cancers of the NSCLC type and not in * del = deletion; ins = insertion. † Three patients had multiple mutations as follows: Japan, patient no. 316, mutations at G719S and S768I; Australia, patient no. 108, mutations at I715S, S720F, and L861Q; Australia, patient no. 364, mutations at E709V, L718L (silent), and G719C. neuroendocrine lung tumors or in cancers (mainly adenocarcinomas) arising at other sites, including those of breast, colorectal, and prostate origins. Preliminary examination of a subset of the tumors indicated that mutations were limited to the fi rst four exons (exons 18 -21) of the TK domain. Three types of mutations constituted 94% of the mutations that we detected: deletions in exon 19, duplications and/or insertions in exon 20, and a singlepoint mutation in exon 21. The remaining 6% of the mutations we detected consisted of rare missense mutations, mainly in exon 18 but also in exons 20 and 21.
We identifi ed 28 distinct mutations and classifi ed them according to type. The three different mutation types -in-frame deletions, single-nucleotide substitutions, and in-frame duplications and/or insertions -all targeted structures around the ATPbinding cleft of EGFR (which is also the docking site of the small-molecule EGFR kinase inhibitors) ( 26 ) , including the phosphate-binding loop (P-loop), the α C-helix, and the activation loop (A-loop). The L858R (M1) single-nucleotide substitution mutation, which is located near the conserved Asp-Phe-Gly sequence, stabilizes the A-loop ( 27 ) . The other two common mutation types were located on either side of the α C-helix in the N lobe ( Fig. 1 ) , which controls the angle of the ATP-binding pocket. We hypothesize that mutations on either side of the α Chelix (deletions in exon 19 and duplications and/or insertions in exon 20) result in similar conformational changes in EGFR that cause a shift in the helical axis that results in the narrowing of the ATP-binding cleft, which leads to increased gene expression and TK inhibitor sensitivity ( 28 ) . At least two of the common mutation types (deletions in exon 19 and the L858R missense mutation) are associated with an increase in the amount and duration of ligand-dependent activation, which explains the much greater sensitivity of cells bearing these mutations to EGFR kinase inhibitors ( 17 ) . Most of the rare mutations target the P-loop. It is interesting that the major mutations always occurred as single mutations in individual tumors, whereas in individual tumors, the rare mutations usually occurred as multiple mutations. These results suggest that the tumorigenic effects of the minor mutations may not be as powerful as those of the major mutations. Additional investigations are required to elucidate the relationships among each type of mutation, TK inhibitor sensitivity, and tumorigenesis.
Our examination of the electropherograms revealed that EGFR TK domain mutations often occurred in a setting of allelic imbalance in which the mutant allele was in excess of the wildtype allele. Polysomy or amplifi cation of the EGFR gene occurs in many cancers, including NSCLC, perhaps relatively early during multistage pathogenesis ( 29 , 30 ) . Our fi ndings suggest that specifi c mutations as well as the increased copy number of the mutant allele may play a role in lung cancer pathogenesis (and perhaps in the response to EGFR-targeted therapy).
Among the unselected patients, there were statistically signifi cantly higher mutation frequencies for those with adenocarcinomas versus other histologies, for never smokers versus ever smokers, for patients from East Asian ethnicity versus other ethnicities, and for females versus males. Of the relatively few adenocarcinomas that arose in patients of East Asian ethnicity who were from United States or Australia, 80% had EGFR TK domain mutations, suggesting that ethnicity was associated with mutation rate, irrespective of geographic location. Results of multivariate analyses confi rmed that these factors (i.e., sex, smoking status, ethnicity, and histologic subtype) were independent. Our results are consistent with those of previous reports ( 17 -19 ) and with fi ndings associated with response to gefi tinib ( 14 , 15 ) . There was no relationship between EGFR TK domain mutation status and either clinical stage or patient survival (in the absence of EGFR kinase inhibitor therapy).
It has been reported that tumors with BAC features have better responses to gefi tinib than tumors without such features ( 20 ) . However, we found no association between EGFR gene mutation status and the BAC subtype of adenocarcinoma, which we defi ned according to the strict noninvasive criteria as stated by the WHO classifi cation of lung tumors ( 25 ) . Many pathologists do not use the strict WHO criteria; instead, they use terms such as " adenocarcinomas with BAC features " (which would be termed " adenocarcinomas with mixed subtypes " by the WHO classifi cation) or " bronchioloalveolar carcinoma and its variants " ( 20 ) . However, even when we applied such a liberal defi nition for the presence of BAC-like features mixed with other adenocarcinoma subtypes to the tumors in our study, there were no statistically signifi cant differences between EGFR TK domain mutation frequencies and the presence or percentage of BAC features. Accurate assessment of BAC features requires examination of the entire tumor block because BAC features are more prominent at the edges of adenocarcinomas of mixed subtypes than elsewhere in the tumor. Thus, the limited tumor material typically assessed by reference pathologists for large multi-institutional studies could possibly lead to misleading classifi cations.
DNA sequences of the high-risk HPV types 16 and 18 have been detected in lung cancers from patients in Taiwan ( 23 ) and, less frequently, from patients in other parts of the world. In Taiwan, these HPV DNA sequences are more frequent in lung cancers that arise in female never smokers than in males or in ever smokers and those cancers are usually of the adenocarcinoma type. Thus, the distribution of HPV DNA sequences in lung cancers has similarities to the distribution of EGFR TK domain mutations. However, we found no relationship between the presence of high-risk HPV DNA sequences and EGFR TK domain mutations in our Taiwanese patients.
Both EGFR TK domain and KRAS gene mutations are relatively frequent in NSCLC, especially in adenocarcinomas ( 31 ) . We found that KRAS gene mutations were more frequent in ever smokers than in never smokers and in patients from Western countries than in patients from East Asian countries. Although mutations in either the EFGR TK domain or the KRAS gene were present in 47% of lung adenocarcinomas, no tumors contained mutations in both genes. Mutant forms of EGFR protein activate multiple downstream signaling pathways, including the RAS, JAK-STAT, and Akt pathways ( 32 -34 ) . Our fi ndings suggest that activation of either the EGFR or RAS signaling pathways has similar effects on lung carcinogenesis.
Mutations in the TP53 gene are also relatively frequent in many cancer types, including lung cancers ( 35 ) . Most KRAS and TP53 gene mutations in lung cancers are G-to-T transversions, molecular events that are believed to be linked to exposure to tobacco smoke carcinogens ( 35 -37 ) . Lung cancers that arise in never smokers rarely have KRAS gene mutations, and their TP53 gene mutations are seldom G-to-T transversions ( 35 , 38 ) , suggesting that these cancers arise in response to exposure to carcinogens other than those present in tobacco smoke.
Although we and others have identifi ed at least 28 different mutations in the TK domain of EGFR, the vast majority of which can be grouped into three major types ( Table 2 ) , to date, only the L858R missense mutation in exon 21 and deletions in exon 19 have been proven to be activating mutations ( 32 ) . Although the activating status of the third major type of mutation (duplications and/or insertions in exon 20) has not been determined, we presume that all mutations of the major types are activating because they always occurred singly, whereas the minor mutations may not be individually suffi cient for activation because they often occurred as multiple mutations in individual tumors. However, this hypothesis will be tested in clinical and in vitro studies. In addition, it is possible that other factors such as gene amplifi cation play a role in tumor pathogenesis and response to TK inhibitors.
The fi ndings presented herein support the hypothesis ( 28 ) that at least two distinct molecular pathways are involved in the pathogenesis of lung adenocarcinomas, one involving EGFR TK domain mutations and the other involving KRAS gene mutations. The different mutational spectra of the KRAS, EGFR, and TP53 genes and the presence of HPV DNA in lung cancers arising in ever and never smokers suggest that exposure to carcinogens in environmental tobacco smoke may not be the major pathogenic factor involved in the origin of lung cancers in never smokers but that an as-yet-unidentifi ed carcinogen(s) plays an important role. The fact that mutations in the TK domain of the EGFR gene are more frequent in lung cancers from patients of East Asian ethnicity than in patients of other ethnicities and have not been identifi ed in other human carcinomas suggests that genetic susceptibility to the hypothetical carcinogen(s) may be greater in some subpopulations than in others. In summary, our fi ndings suggest that mutations in the EGFR TK domain occur in a subset of lung adenocarcinomas, whereas KRAS gene mutations occur in a different subset. EGFR TK domain mutations are the fi rst molecular change known to occur specifi cally in never smokers.
